Alprolix: Innovation in Treatment for Patients with Deficient or Dysfunctional Factor IX

FcRn is believed to allow Aliprolyx to use the natural pathway to prolong plasma half-life. Alprolix is ​​ultimately the first long-acting coagulation factor IX remedy, reduces frequent product injections and improves patient care management. Product category / type Alprolix is ​​classified as a therapeutic bio-recombinant plasma derivative, which is a recombinant fusion comprising a human Factor IX sequence that binds to the human Fc region for its active ingredient factor IX (recombinant) It is a protein. Immunoglobulin G1 (IgG1).

Activation of factor IX and its cofactor, activated factor VIII, is important for proteolytic activation of factor X. Genetic defects of these factors cause hemophilia B and hemophilia A hemorrhagic diseases, respectively. Development of a recombinant expression system of Factor VIII following isolation of F8 gene 1 is a significant advance in the treatment of hemophilia A. Currently, several methods for altering the hemophilia A phenotype by cell therapy and / or gene therapy are under development.

Searching for the origin of factor VIII synthesis and its effect on haemophilia A treatment strategy

FcRn is believed to allow Aliprolyx to use the natural pathway to prolong plasma half-life. Alprolix is ​​ultimately the first long-acting coagulation factor IX remedy, reduces frequent product injections and improves patient care management. - The stars are divided into low quality stars and high quality stars. This nebula is an interstellar cloud in space, consisting of dust, hydrogen and helium, and plasma. It is formed when gravity is attracted. The hydrogen fusion rate is very slow and lasts for a long time. Just dissolve hydrogen at the center, the center is not that large

New treatments for molybdenum cofactor deficiency are being studied. Supplementation of cyclic pyrylphosphate in patients with type A deficiency corrects metabolic disorders and prevents neurological deterioration Patients with type B deficiency do not lack this molecule and can not benefit from this treatment. However, recent studies have shown that supplementation of pyridoxine in these patients can relieve pain by eliminating stroke. (Detailed information) The amount of molybdenum in food depends on the amount of molybdenum in the soil, but this is very different. Changes in the incidence of esophageal cancer around the world are related to the amount of molybdenum in soil and food. Similar observations have been made to determine factors related to the prolongation of the population. (Details)